Journal article
Patient-derived xenograft (PDX) models in basic and translational breast cancer research
LE Dobrolecki, SD Airhart, DG Alferez, S Aparicio, F Behbod, M Bentires-Alj, C Brisken, CJ Bult, S Cai, RB Clarke, H Dowst, MJ Ellis, E Gonzalez-Suarez, RD Iggo, P Kabos, S Li, GJ Lindeman, E Marangoni, A McCoy, F Meric-Bernstam Show all
Cancer and Metastasis Reviews | SPRINGER | Published : 2016
Abstract
Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research. In breast cancer, to complement the now curated collection of approximately 45 long-established human breast cancer cell lines, a newly formed consortium of academic laboratories, currently from Europe, Australia, and North America, herein summarizes data on over 500 stably transplantable PDX models representing all three clinical subtypes of breast cancer (ER+, HER2+, and “Triple-negative” (TNBC)). Many of these models are well-characterized with respect to genomic, transcripto..
View full abstractGrants
Awarded by National Breast Cancer Foundation
Funding Acknowledgements
Samuel Aparicio-Supported by the BC Cancer Foundation, Canadian Breast Cancer Foundation, CIHR, Canadian Foundation for Innovation, Stand Up to Cancer Canada, Canadian Cancer Research Institute, and Terry Fox Research Institute Fariba Behbod-Supported by R01-NIH/NCI-R01CA172764, NIH/NCI-R21CA187890, AACR-Breast Cancer Research Foundation-2014 Translational Breast Cancer Research, and NIH/NCI-R21CA185460 Cathrin Brisken-The research leading to these results has received support from the Swiss Cancer League, the SNF, and the Innovative Medicines Initiative Joint Undertaking (grant agreement no. 115188) for the PREDECT consortium (www.predect.eu) resources composed of financial contribution from EU-FP7 and EFPIA companies in kind contribution. The Web address of the Innovative Medicines Initiative is http://www.imi.europa.eu/. Carol J. Bult-This work was supported in part by the Maine Cancer Foundation, The Jackson Laboratory Director's Innovation Fund, and JAX Cancer Center grant P30 CA034196. Robert Clarke and Denis Alferez-This work was funded by Cancer Research UK and Breast Cancer Now. We would like to thank all patients who donated tissue to this study and the Manchester Cancer Research Centre Biobank for consenting patients and collecting tissue. Eva Gonzalez-Suarez-This work was supported in part by grants to Eva Gonzalez Suarez by the Spanish Ministry of Economy and Competitivity MINECO and from the ISCIII (SAF2008-01975, SAF2011-22893, SAF2014-55997), PIE13/00022, co-funded by FEDER funds/European Regional Development Fund (ERDF-a way to build Europe), by a Career Catalyst grant from the Susan Komen Foundation and by institutional funds provided by the Generalitat de Catalunya. Richard Iggo-This work was supported by the "Fondation pour la lutte contre le cancer et pour des recherches medico-biologiques," the INCa-DGOS-INSERM 6046 SIRIC BRIO grant, and the French Cancer League (Comite de la Charente Maritime). Peter Kabos-NIH grant CA164048, Grohne Cancer Research Fund Michael T. Lewis-This work was supported in part by the Breast Cancer Research Foundation, the Emma Jacobs Clinical Breast Cancer Fund, the Susan G. Komen Foundation, Cancer Fighters of Houston, BCM Cancer Center grant P30 CA125123, BCM Breast Cancer SPORE P50 CA50183, NIH/NCI grant R01 CA112305, and NIH/NCI grant U54 CA149196. The authors also acknowledge the joint participation by Diana Henry Helis Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with Baylor College of Medicine and its "Blood-borne BioMarkers for Detection of Breast Cancer" Program. Shunqiang Li-Susan G. Komen for the Cure (BCTR0707808, KG090422, and PG12220321), Breast Cancer Research Foundation, CTSA grant UL1 RR024992, and The Fashion Footwear Charitable Foundation, Inc. Geoffrey J. Lindeman and Jane E. Visvader-Received funding support from the Australian National Health and Medical Research Council (NHMRC; 1016701, 1040978, 1086727, 1085191); NHMRC Independent Research Institute Infrastructure Support Scheme (IRIISS) (to WEHI); the Victorian State Government through the Victorian Cancer Agency and Operational Infrastructure Support; the National Breast Cancer Foundation (Australia); the Cancer Therapeutics CRC; and the Australian Cancer Research Foundation. G.J.L. is supported by an NHMRC Research Fellowship (1078730); J.E.V. is supported by an NHMRC Australia Fellowship (1037230). Helen Piwnica-Worms-This work was supported in part by the Cazalot Breast Cancer Model Resource, The Susan G. Komen Foundation, and The Cancer Prevention and Research Institute of Texas (CPRIT) RP150148. Jorge Reis-Filho-Research reported in this publication was supported in part by a grant from the Breast Cancer Research Foundation and a Cancer Center Support grant of the National Institutes of Health/National Cancer Institute (grant no. P30CA008748). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Carol Sartorius-NIH grant CA140985. Alana Welm-The Noreen Fraser Foundation, METAvivor Foundation, AACR Susan G. Komen Career Catalyst award, DOD Breast Cancer Research Program grants W81XWH-08-1-0109 and BC112623, and NIH/NCI grants 1R01CA166422 and 1R01CA173903 Max Wicha-R35: CA129765; RO1 CA101860, Komen for the Cure Promise grant, and Breast Cancer Research Foundation grant